ADIAL PHARMACEUTICALS, INC. (ADIL) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-09

Key Insights

CEO Cary J. Claiborne has been granted 37,985 restricted shares of Adial Pharmaceuticals' common stock, which will vest in full on the earlier of the one-year anniversary of the grant date or a change of control event.
This insider grant suggests Claiborne's continued commitment to the company and alignment with shareholder interests through equity-based compensation.
The vesting schedule, tied to either time or a change of control, provides incentives for Claiborne to drive long-term value creation for Adial Pharmaceuticals.

Want the newest filings?

This analysis covers the filing from 2026-04-09. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-09

The reporting person, Robertson H. Gilliland, received a grant of 9,185 shares of restricted common stock of Adial Pharmaceuticals, Inc. (ADIL), which vest in full on the earlier of one year from the grant date or upon a change of control.
The grant of restricted shares aligns the reporting person's interests with those of the company and its shareholders, as the vesting is tied to continued service and a potential change of control event.
The reporting person's direct ownership of 9,185 shares following the reported transaction represents a direct ownership stake in the company, indicating the reporting person's commitment to and confidence in Adial Pharmaceuticals' future.

Filed: 2026-04-09

Vinay Shah, the Chief Financial Officer of Adial Pharmaceuticals, acquired 17,325 shares of the company's common stock, which vest in full on the earlier of one year from the grant date or a change of control event.
This direct acquisition of shares by a key executive officer suggests their confidence in the company's future prospects and aligns their incentives with those of shareholders.
The vesting terms of the restricted stock grant, with accelerated vesting on a change of control, may indicate the company is positioning itself for a potential acquisition or other significant corporate event.

Filed: 2026-04-09

The reporting person, Kevin Schuyler, acquired 9,185 shares of common stock of ADIAL PHARMACEUTICALS, INC. (ADIL) at no cost, indicating an award or grant of restricted shares.
Schuyler also owns an additional 4 shares indirectly through his wife, Carolyn M. Schuyler, and 230 shares through MVA 151 Investors, LLC, which he controls.
The restricted share grant vests in full on the earlier of the one-year anniversary of the grant date or a change of control, subject to Schuyler's continued service to the company.

Filed: 2026-04-09

J. Kermit Anderson, a director of Adial Pharmaceuticals, Inc. (ADIL), has been granted 9,185 stock options on April 7, 2026, with a strike price of $1.64. The options vest in full on the earlier of the one-year anniversary of the grant date or a change of control event, subject to Anderson's continued service.
This stock option grant indicates that the company is incentivizing its directors, potentially to align their interests with those of shareholders and support the long-term growth of the business.
The timing of the grant, which is close to the filing date, suggests that the company may be experiencing a positive development or is preparing for a significant event, such as a change of control.

Filed: 2026-04-09

Tony Goodman, the Chief Operating Officer, acquired 26,510 shares of Adial Pharmaceuticals, Inc. (ADIL) common stock, representing a direct ownership increase of 0.13%.
The shares were granted as restricted stock with a one-year vesting period or upon a change of control event, aligning Goodman's interests with shareholders.
This insider buying activity suggests Goodman's confidence in the company's outlook and potential for value creation.

Other reports for ADIAL PHARMACEUTICALS, INC.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.